Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison

Urology Annals

Volumn 5, Issue 1, 2013, Pages 7-12

  Inamoto, Teruo ^a   Ubai, Takanobu ^a   Nishida, Takeshi ^a   Fujisue, Yutaka ^a   Katsuoka, Yoji ^a   Azuma, Haruhito ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Bacillus Calmette Gu rin; bladder cancer; intravesical instillation; Tokyo 172 strain

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; CANCER GROWTH; CLINICAL ARTICLE; CONNAUGHT STRAIN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSURIA; EPIDIDYMITIS; FATIGUE; FEMALE; HEMATURIA; HUMAN; LEG EDEMA; LOW DRUG DOSE; MALE; MORBIDITY; NON MUSCLE INVASIVE BLADDER CANCER; PENILE EDEMA; PENIS DISEASE; POLLAKISURIA; PRIORITY JOURNAL; PRURITUS; PYURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; STRAIN DIFFERENCE; TOKYO 172 STRAIN; TREATMENT DURATION; TREATMENT RESPONSE; URINE RETENTION;

EID: 84875748786     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.106873     Document Type: Article

References (24)

1. Mack D, Frick J. Low-dose bacille Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: A phase II study with the BCG strain Connaught Canada. Br J Urol 1995;75:185-7.
2. Kamel AI, El Baz AG, Abdel Salam WT, El Din Ryad ME, Mahena AA. Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: Long term results. J Egypt Natl Canc Inst 2009;21:151-5.
3. Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ. Update on the Dutch Cooperative Trial: Mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin Urol Oncol 1996;14:10-6.
4. Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence. Int J Urol 2003;10:183-9.
5. Mugiya S, Ozono S, Nagata M, Takayama T, Ito T, Maruyama S, et al. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: Results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005;35:395-9.
6. Akaza H, Kameyama S, Kakizoe T, Kojima H, Koiso K, Aso Y, et al. Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group. Nihon Hinyokika Gakkai Zasshi 1992;83:183-9.
7. Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol 1995;27:723-33.
8. Ozono S, Takahashi K, Tanaka N, Momose H, Hirao Y, Okajima E. Intravesical bacillus Calmette-Guerin (BCG) therapy for carcinoma in situ of the urinary bladder-outcomes of a randomized study. Ann Soc BCG BRM Immunother 1996;20:95-100.
9. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000;37:9-15.
10. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 1999;162:2399-405.
11. Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, et al. Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: Historical cohort study. Urology 2008;71:1161-5.
12. Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, et al. Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996;48:957-61; discussion 961-2.
13. Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani C. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995;27:19-22.
14. Pagano F, Bassi P, Milani C, Meneghini A, Tuccitto G, Garbeglio A, et al. Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: Preliminary results. Prog Clin Biol Res 1989;310:253-61.
15. Mack D, Frick J. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology 1995;45:958-61.
16. Mack D, Frick J. Low-dose BCG in superficial bladder cancer with strain Connaught Canada-as effective as strain Pasteur Paris? Eur J Cancer 1994;30A:1728-9.
17. Lebret T, Gaudez F, Hervé JM, Barré P, Lugagne PM, Botto H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: Recurrence, progression and success. Eur Urol 1998;34:67-72.
18. Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology 2008;71:297-301.
19. Morales A, Nickel JC, Wilson JW. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992;147:1256-8.
20. Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, et al. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol 2001;165:401-3.
21. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: Long-term results. J Urol 2000;163:68-71; discussion 71-2.
22. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
23. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol 1996;156:1602-5.
24. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF, Jr., et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995;13:1404-8.